|
|
|||||||||
Clinical Investigations |
1 Institute of Clinical Physiology, National Research Council, Pisa, Italy
The aim of this study was to compare 99mTc-tetrofosmin SPECT with contrast-enhanced MRI (ceMRI), a new direct sign of myocardial fibrosis. Methods: We studied 21 patients (age, 60 ± 11 y; 19 male) with previous myocardial infarction and severe left ventricular dysfunction (ceMRI EF, 29% ± 6%). All patients underwent resting and postnitrate (intravenous isosorbide dinitrate) 99mTc-tetrofosmin gated SPECT as well as ceMRI. Scintigraphic analysis was performed using quantitative perfusion SPECT (QPS), providing the percentage radiotracer uptake and defect severity in a 20-segment model. Hyperenhancement was defined by the increase of ceMRI signal intensity 20 min after intravenous injection of gadoliniumdiethylenetriaminepentaacetic acid and its regional extension as the percentage of the total segment area. Results: In ceMRI dysfunctional segments, the correlation between the extent of hyperenhancement and both 99mTc-tetrofosmin uptake and defect severity was significantly better after nitrate administration rather than at rest (P < 0.0001). Using a ceMRI cutoff below 40%, 102 of 196 (52%) segments were viable, whereas 94 (48%) segments were not viable. According to receiver-operating characteristic curve analysis, diagnostic accuracies were higher for postnitrate 99mTc-tetrofosmin uptake as well as perfusion defect severity than using resting data (0.84 vs. 0.71, P < 0.001; 0.89 vs. 0.76, P < 0.001, respectively). Conclusion: After nitrate administration, 99mTc-tetrofosmin uptake and perfusion defect severity were closely related to ceMRI, demonstrating, in vivo, the existence of an inverse correlation between the transmural distribution of fibrosis and tracer delivery to the myocardium.
Key Words: myocardial viability gated SPECT contrast-enhanced MRI nitrates
Related articles in JNM:
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |